Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol.
Goedken, E.R., Argiriadi, M.A., Banach, D.L., Fiamengo, B.A., Foley, S.E., Frank, K.E., George, J.S., Harris, C.M., Hobson, A.D., Ihle, D.C., Marcotte, D., Merta, P.J., Michalak, M.E., Murdock, S.E., Tomlinson, M.J., Voss, J.W.(2015) J Biol Chem 290: 4573-4589
- PubMed: 25552479 
- DOI: 10.1074/jbc.M114.595181
- Primary Citation of Related Structures:  
4QPS - PubMed Abstract: 
The action of Janus kinases (JAKs) is required for multiple cytokine signaling pathways, and as such, JAK inhibitors hold promise for treatment of autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. However, due to high similarity in the active sites of the four members (Jak1, Jak2, Jak3, and Tyk2), developing selective inhibitors within this family is challenging ...